NeuroDex and Stanford Publish First Blood-Based Evidence of CNS Target Engagement for GLP-1 and PPARγ Agonists

NATICK, MA, UNITED STATES, April 22, 2026 /EINPresswire.com/ -- NeuroDex and Stanford Researchers Publish First ...
News-Medical.Net

Multimodal AI improves prediction of PIK3CA mutations in breast cancer

Breast cancer is one of the most common malignancies worldwide, and mutations in the PI3K/AKT/mTOR (PAM) signaling pathway ...
Technology Networks

Two Successive "Hits" to DNA Trigger Drug-Resistant Childhood Epilepsy

Brain organoids reveal that two genetic mutations in DEPDC5 drive epilepsy, disrupting early brain development, and causing ...
AlphaGalileo

New AI framework offers reliable, cost-effective prediction of PIK3CA mutations in breast cancer

Accurate detection of PIK3CA mutations is essential for personalizing breast cancer treatment, particularly with ...

Lab-grown mini-brains shed light on childhood epilepsy

Why does the same genetic mutation cause a severe brain malformation in some patients but not in others? Researchers from the MOSAIC team at the Paris Brain Institute have developed mosaic human ...

Robust flu protection may rely on B cells that are long-lived residents in the lungs

Deep in the lungs, resident memory B cells stand guard against influenza reinfection—but whether they remain there may depend ...
The Manila Times

Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort

Detailed data for the gedatolisib triplet and doublet regimens will be presented at a late-breaking abstract oral session at the 2026 ASCO Annual Meeting ...
European Medical Journal

Lupus Treatment Enters Precision Immunotherapy Era

Precision immunotherapy strategies are redefining systemic lupus erythematosus treatment by targeting immune pathways. Read ...
AlphaGalileo

RagC senses β-hydroxybutyrate abundancy to suppress mTORC1 and tumor growth

While the ketogenic diet has emerged as a promising nutritional intervention in cancer therapy, the core signaling pathway ...

Rakovina Therapeutics Presents New Preclinical Data at AACR 2026 Annual Meeting

Rakovina Therapeutics Inc. (TSX-V: RKV; FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, today announced the ...

Lirum Therapeutics Announces Positive LX-101 Data Selected for Presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting

Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that new LX-101 data in Ewing sarcoma has ...